Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO) will likely be releasing its earnings data before the market opens on Wednesday, March 12th. Analysts expect Spero Therapeutics to post earnings of ($0.31) per share and revenue of $6.20 million for the quarter.

Spero Therapeutics Trading Down 0.1 %

SPRO stock opened at $0.77 on Wednesday. The firm has a market cap of $41.95 million, a P/E ratio of 10.99 and a beta of 0.68. Spero Therapeutics has a 1-year low of $0.74 and a 1-year high of $1.89. The business’s 50 day moving average is $0.89 and its 200-day moving average is $1.12.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Finally, Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a report on Friday, December 20th.

Insider Buying and Selling

In related news, Director Ankit Mahadevia sold 69,219 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $53,990.82. Following the sale, the director now owns 689,866 shares in the company, valued at $538,095.48. This represents a 9.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $121,159.74. Following the completion of the sale, the chief executive officer now directly owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. The trade was a 8.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 245,241 shares of company stock valued at $191,288 over the last 90 days. 4.52% of the stock is owned by insiders.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.